Symbio

Symbio

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Symbio is a privately held, specialized contract research organization (CRO) that offers comprehensive clinical trial services exclusively for dermatology, aesthetics, gastroenterology, and inflammation. With a claimed history of over 20 years of collective experience, the company supports over 650 trials across 85+ indications and cites involvement in 70+ FDA approvals. Its business model is entirely service-based, providing functional and full-service CRO solutions, including a unique in-house topical formulation development subsidiary, to biopharma and medical device sponsors.

DermatologyAestheticsGastroenterologyInflammation

Technology Platform

Integrated suite of in-house clinical trial services with specialized therapeutic expertise in dermatology, aesthetics, gastroenterology, and inflammation. Includes a subsidiary (Dow Development Laboratories, LLC) for turnkey topical formulation development.

Opportunities

Growing global R&D spend in dermatology, aesthetics, and gastroenterology fuels demand for specialized CRO services.
Symbio's integrated model, including topical formulation development, offers a unique value proposition that can attract sponsors seeking deep expertise and efficient trial execution in these complex areas.

Risk Factors

Business is highly dependent on client outsourcing budgets and the health of R&D pipelines in its niche areas.
Faces intense competition from both large global CROs and other niche players.
Operational performance and client retention are critical to maintaining reputation and revenue.

Competitive Landscape

Symbio competes in the crowded CRO market, differentiated by its narrow therapeutic focus. It competes against large, diversified CROs (e.g., IQVIA, PPD) on specialization and against other boutique CROs on the breadth of its integrated in-house services and its unique topical formulation development capability.